Mood Emot.  2018 Jul;16(2):86-95. 10.0000/me.2018.16.2.86.

Korean Medication Algorithm for Bipolar Disorder 2018 : Maintenance Therapy

  • 1Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University and Paik Institute for Clinical Research, Busan, Korea.
  • 2Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
  • 3Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 4Department of Psychiatry, Naju National Hospital, Naju, Korea.
  • 5Department of Psychiatry, Sacred Heart Hospital, Hallym University, Anyang, Korea.
  • 6Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea.
  • 7Department of Psychiatry, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
  • 8Department of Psychiatry, Jeju National University Hospital, Jeju, Korea.
  • 9Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation, Uiwang, Korea.
  • 10Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University, Cheonan, Korea.
  • 11Department of Psychiatry, Myongji Hospital, Goyang, Korea.
  • 12Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea.


In this study, we evaluated the maintenance-treatment strategies of bipolar I and bipolar II disorders of KMAP-BP 2018.
The questionnaire used to survey experts for their opinions of medication used for the treatment of bipolar disorder was completed by the review committee consisting of 84 experienced psychiatrists. It is composed of 50 questions, and each question includes various sub-items. The questionnaire for maintenance treatments was composed of overall treatment strategies after acute mood episodes in bipolar I and II disorders, including the choice of antipsychotic and antidepressant drugs, duration of medication, and treatment strategies used to achieve a breakthrough in symptoms.
In case of bipolar I disorder, mood stabilizer monotherapy, a combination of mood stabilizer and atypical antipsychotic drugs, and atypical antipsychotic drug monotherapy were the first-line treatments. In maintenance management for bipolar II disorder, combinations of mood stabilizer and mood stabilizer monotherapy or atypical antipsychotic monotherapy were preferred. Atypical antipsychotic drugs were favored as the maintenance treatment for bipolar I and II disorders in KMAP-BP 2018.
There have been growing bodies of tendency that atypical antipsychotics are more preferred than previously in the KMAP-BP 2014.


Bipolar disorder; KMAP-BP 2018; Maintenance therapy

MeSH Terms

Advisory Committees
Antidepressive Agents
Antipsychotic Agents
Bipolar Disorder*
Mood Disorders
Antidepressive Agents
Antipsychotic Agents
Full Text Links
  • ME
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: